S1PR2 (sphingosine-1-phosphate receptor 2) is a G protein-coupled receptor (GPCR) that binds sphingosine-1-phosphate (S1P), a bioactive lipid regulating diverse physiological processes. Part of the S1PR family (S1PR1-5), S1PR2 is widely expressed in immune cells, endothelial cells, and tissues like the liver, lungs, and brain. It plays key roles in cell migration, vascular development, immune response modulation, and tissue homeostasis. Dysregulation of S1PR2 signaling is linked to pathologies including cancer progression, fibrosis, inflammatory disorders, and neurological diseases. For instance, S1PR2 promotes tumor angiogenesis and metastasis in certain cancers but may exert protective effects in liver fibrosis.
S1PR2 antibodies are critical tools for detecting receptor expression, localization, and activation in research. They enable studies on S1PR2’s dual roles in health and disease, often revealing context-dependent mechanisms. Therapeutic interest in targeting S1PR2 has grown, with antibodies explored for blocking pathogenic signaling in cancers or inflammatory conditions. However, challenges remain, such as receptor subtype specificity and understanding tissue-specific signaling cascades. Current research also focuses on developing small-molecule inhibitors or monoclonal antibodies to modulate S1PR2 activity, balancing efficacy with minimizing off-target effects. Overall, S1PR2 antibodies remain pivotal in unraveling the receptor’s complex biology and translational potential.